Your browser is no longer supported. Please, upgrade your browser.
URGN [NASD]
UroGen Pharma Ltd.
Index- P/E- EPS (ttm)-6.39 Insider Own1.20% Shs Outstand22.06M Perf Week0.33%
Market Cap484.89M Forward P/E- EPS next Y-4.65 Insider Trans2.13% Shs Float19.28M Perf Month12.06%
Income-136.90M PEG- EPS next Q-1.37 Inst Own75.50% Short Float13.95% Perf Quarter4.63%
Sales3.80M P/S127.60 EPS this Y-6.70% Inst Trans1.38% Short Ratio16.02 Perf Half Y-12.94%
Book/sh5.46 P/B3.85 EPS next Y21.50% ROA-81.70% Target Price- Perf Year-32.26%
Cash/sh5.18 P/C4.05 EPS next 5Y- ROE-92.20% 52W Range13.12 - 33.70 Perf YTD16.54%
Dividend- P/FCF- EPS past 5Y-65.20% ROI- 52W High-37.69% Beta1.31
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin90.70% 52W Low60.08% ATR1.00
Employees187 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)58.54 Volatility4.58% 5.36%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.80% Profit Margin- Rel Volume0.98 Prev Close20.91
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume167.94K Price21.00
Recom1.70 SMA206.89% SMA504.06% SMA200-7.13% Volume164,130 Change0.43%
Apr-16-20Reiterated H.C. Wainwright Buy $53 → $57
Apr-13-20Reiterated H.C. Wainwright Buy $75 → $53
Jan-09-20Initiated National Securities Neutral $37
May-30-19Initiated JP Morgan Neutral
May-29-19Initiated Goldman Neutral
Jan-29-19Initiated H.C. Wainwright Buy $82
Nov-08-18Resumed Jefferies Buy
Apr-04-18Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18Initiated Ladenburg Thalmann Buy $50
Nov-15-17Reiterated Oppenheimer Outperform $32 → $51
Nov-15-17Downgrade Raymond James Outperform → Mkt Perform
Jan-19-21 07:00AM  
Jan-13-21 08:00AM  
Jan-06-21 08:00AM  
Dec-18-20 04:36AM  
Dec-16-20 07:20AM  
Dec-11-20 08:35AM  
Dec-07-20 07:00AM  
Dec-04-20 08:42AM  
08:00AM  
Dec-03-20 08:00AM  
Nov-29-20 07:57PM  
Nov-17-20 08:00AM  
Nov-12-20 08:00AM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 07:00PM  
08:33AM  
08:00AM  
06:30AM  
Nov-02-20 08:00AM  
Oct-27-20 06:50AM  
Oct-07-20 12:58PM  
Oct-05-20 08:00AM  
Sep-15-20 12:14PM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-04-20 08:00AM  
Aug-27-20 08:00AM  
Aug-10-20 05:00PM  
08:33AM  
08:00AM  
Aug-03-20 08:00AM  
Jun-15-20 08:43PM  
Jun-05-20 08:00AM  
Jun-01-20 08:00AM  
May-15-20 09:01AM  
09:00AM  
May-09-20 02:31PM  
May-07-20 08:00AM  
May-01-20 08:00AM  
Apr-30-20 09:05AM  
08:00AM  
Apr-21-20 12:34PM  
Apr-16-20 10:37AM  
08:09AM  
Apr-15-20 06:22PM  
Apr-06-20 08:53AM  
Apr-03-20 08:00AM  
Mar-23-20 08:00AM  
Mar-16-20 11:45AM  
Mar-06-20 08:00AM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Feb-24-20 08:00AM  
Jan-30-20 08:59AM  
Jan-08-20 08:00AM  
Dec-19-19 08:00AM  
Dec-17-19 07:36PM  
Dec-16-19 12:00PM  
Dec-06-19 08:00AM  
Dec-01-19 03:06PM  
Nov-18-19 08:00AM  
Nov-12-19 08:00AM  
07:20AM  
Nov-11-19 08:00AM  
Nov-06-19 10:16AM  
08:00AM  
Sep-30-19 08:00AM  
Sep-24-19 04:01PM  
10:25AM  
Sep-18-19 12:15PM  
Sep-10-19 08:00AM  
Sep-06-19 04:05PM  
Aug-13-19 03:05PM  
Aug-12-19 04:23PM  
Aug-10-19 07:11AM  
Aug-09-19 08:00AM  
Aug-05-19 08:00AM  
Jul-23-19 10:43AM  
Jul-16-19 09:48AM  
Jul-05-19 05:14PM  
Jul-01-19 08:00AM  
May-30-19 08:00AM  
May-26-19 08:18AM  
May-20-19 12:48PM  
May-09-19 01:23PM  
08:00AM  
May-07-19 12:53PM  
May-06-19 11:00AM  
May-05-19 04:25PM  
May-02-19 08:00AM  
Apr-23-19 08:00AM  
Apr-20-19 07:02PM  
Apr-16-19 10:21AM  
Apr-05-19 09:12AM  
Mar-25-19 02:39PM  
Mar-05-19 08:00AM  
Feb-28-19 11:37AM  
08:00AM  
Feb-21-19 08:00AM  
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Barrett Elizabeth A.Chief Executive OfficerDec 14Buy18.5010,000185,000229,117Dec 15 05:27 PM
Barrett Elizabeth A.Chief Executive OfficerDec 04Option Exercise0.0061,6520219,117Dec 04 04:35 PM
Schoenberg MarkChief Medical OfficerDec 04Sale19.8566213,14119,723Dec 07 03:59 PM
Schoenberg MarkChief Medical OfficerOct 26Sale20.951012,11619,343Oct 28 02:12 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerOct 15Sale21.772,40052,24810,405Oct 16 03:41 PM
Schoenberg MarkChief Medical OfficerSep 04Sale20.203487,03019,236Sep 08 04:48 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerSep 01Sale22.8250911,6157,888Sep 01 02:37 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJul 27Sale23.511413,3157,355Jul 28 05:34 PM
Schoenberg MarkChief Medical OfficerJul 27Sale23.51701,64618,543Jul 28 05:32 PM
Schoenberg MarkChief Medical OfficerJun 04Sale27.513499,60218,404Jun 05 02:31 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerMay 20Sale25.073588,9757,079May 20 04:44 PM
Barrett Elizabeth A.Chief Executive OfficerMay 12Option Exercise0.0035,2290157,465May 14 01:07 PM
Schoenberg MarkChief Medical OfficerApr 27Sale24.35701,70517,711Apr 28 01:53 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerApr 27Sale24.351413,4336,396Apr 28 01:51 PM
Mullennix StephenChief Operating OfficerApr 27Sale24.351453,53110,084Apr 28 01:43 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 20Sale29.6836010,6856,120Feb 24 04:53 PM
Mullennix StephenChief Operating OfficerFeb 14Sale28.0461217,1609,812Feb 18 02:33 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJan 27Sale29.2866719,5304,438Jan 28 05:15 PM
Mullennix StephenChief Operating OfficerJan 27Sale29.2668420,0148,665Jan 28 05:14 PM
Schoenberg MarkChief Medical OfficerJan 27Sale29.153229,3869,177Jan 28 05:10 PM